Jaffer A Ajani
M.D. Anderson Cancer Center · UT MD Anderson Cancer Center · U.S. studies
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jaffer A Ajani as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:54 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04522336 · Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal CancerM.D. Anderson Cancer Center · completed · Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 · principal investigator
- Early Ph1NCT03395847 · Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal AdenocarcinomaM.D. Anderson Cancer Center · completed · Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8 · principal investigator
- Ph1/Ph2NCT02530437 · Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction CancerM.D. Anderson Cancer Center · terminated · Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Adenocarcinoma AJCC v7, Stage II Esophageal Adenocarcinoma AJCC v7 · principal investigator
- Ph1/Ph2NCT00964080 · Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal AdenocarcinomaMebiopharm Co., Ltd · unknown · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma · principal investigator
- Ph3NCT00002551 · SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically RemovedSWOG Cancer Research Network · completed · Colorectal Cancer · study chair
- Ph3NCT00075868 · Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal CancerRadiation Therapy Oncology Group · completed · Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ · study chair
- Ph2NCT00006081 · Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach CancerM.D. Anderson Cancer Center · completed · Esophageal Cancer, Gastric Cancer · study chair
- Ph3NCT00003596 · Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal CancerRadiation Therapy Oncology Group · completed · Anal Cancer · study chair
- Ph2NCT00003862 · Chemotherapy and Radiation Therapy in Treating Patients With Stomach CancerRadiation Therapy Oncology Group · completed · Gastric Cancer · study chair
- Ph2NCT00009880 · Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or StomachRadiation Therapy Oncology Group · completed · Esophageal Cancer, Gastric Cancer · study chair
- Ph2NCT00042510 · Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal CancerCancer Advances Inc. · completed · Stomach Neoplasms, Esophageal Neoplasms · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Inhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE junctionR01CA172741 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2013 to 2017 · $279,793 awarded in 2017Same name and institution; not confirmed by an ID
- Prediction of Pathologic Complete Response by Gene Expression Profiling in EsophaR01CA138671 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2010 to 2014 · $300,665 awarded in 2014Same name and institution; not confirmed by an ID
- Molecular Biomarkers as Classifiers to Individualize Therapy of Esophagus CancerR21CA129906 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2009 to 2010 · $183,294 awarded in 2010Same name and institution; not confirmed by an ID
- Molecular Markers of Response to Chemoradiation in Localized Esophageal CancerR21CA127672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2008 to 2009 · $138,600 awarded in 2009Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Southwest Oncology Group Treatment GrantU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHARLES D. BLANKE · fiscal years 2013Named on NCT00002551
- U01CA070172RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT00006081
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT00006081
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:54 UTC. The ranking covers the 200 most relevant of 115 PubMed records, and a shared surname and initials can bring in a namesake. All 115 on PubMed
- Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.N Engl J Med · 20012,705 citationsRCR 66.6
- 2,656 citationsRCR 153.2
- 1,603 citationsRCR 39.2
- 1,556 citationsRCR 88.3
- 1,050 citationsRCR 71.3
- 778 citationsRCR 69.3
- 657 citationsRCR 16.4
- Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.J Clin Oncol · 2012644 citationsRCR 19.7
- 627 citationsRCR 54.7
- 455 citationsRCR 14.4